Pre-market hot trades in US stocks: Novo Nordisk's oral weight loss drug approved by FDA, stock price rises 3.02% in pre-market, attracting market attention

Pre-market Hot Trades in US Stocks Novo Nordisk AS pre-market rose by 3.02%. Based on recent news, On January 5, Novo Nordisk announced the launch of the oral version of Wegovy in the United States, with a cash price starting at $149 per month, and expanded distribution channels through major pharmacies and telemedicine. This move significantly raised market expectations for its weight loss drug, driving the stock price up. On January 5, the US FDA approved the oral version of semaglutide weight loss drug from Novo Nordisk for reducing the risk of major cardiovascular events in adults with obesity and diagnosed cardiovascular disease. The launch of this drug further boosted investor confidence, with the stock price surging over 5%. On January 6, analysts adjusted their ratings and target prices for Novo Nordisk, with FactSet data showing that 27 analysts raised the median target price to $61.51, an increase of 4.32%. This positive analyst expectation also supported the stock price. The competition in the weight loss drug market is intensifying, and the prospects for oral medications are broad. Top Gainers in Pre-market US Stocks Rich Sparkle, pre-market rose by 93.80%, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. La Rosa pre-market rose by 52.56%. Based on recent key news: On January 9, La Rosa Holdings announced the completion of the initial phase of a $250 million financing, with CEO Joe La Rosa stating that this will enhance the company's investment assets and drive the execution of AI infrastructure. This news propelled the stock price up by 53.85% in pre-market. Source: Zhitong Finance On January 9, the company completed a $11 million convertible note financing, planning to use these funds to expand its AI infrastructure strategy and further enhance real estate data center facilities. This move increased market confidence in the company's future growth. Source: Wall Street Insight On January 9, despite the company's cost-cutting measures and financing strategy, valuation remains constrained due to losses and lack of dividend yield. Technical sentiment signals indicate a sell, and the market remains cautious about the company's long-term performance. Source: Jinshi Data. Significant capital inflow in the real estate and AI industries, with risks needing attention. RenX Enterprises pre-market rose by 43.65%. Based on recent key news: On January 6, RenX Enterprises completed a debt restructuring, transferring the Lago Vista property to the lender, with a conditional valuation of $5 million. This move strengthened the company's balance sheet and shifted its strategic focus towards resource groups. On January 7, RenX Enterprises purchased a Komptech Crambo shredder and a Diamond Z horizontal grinder for a total price of approximately $2.54 million. The acquisition of this equipment expanded the company's equipment base and supported its growth plans On January 7th, RenX Enterprises signed a transferable promissory note and guarantee agreement with Commercial Credit Group to finance the purchase of crushing and grinding equipment. This move reflects the company's cautious approach to capital allocation. The industry has significant growth potential, and attention should be paid to macroeconomic changes